As of June 10, 2025, Genmab A/S (GMAB.CO) reports a Net Margin of 5.55%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Genmab A/S's Net Margin
Over recent years, Genmab A/S's Net Margin has shown significant volatility. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | 5.55% |
| 2023-12-31 | 4.02% |
| 2022-12-31 | 5.69% |
| 2021-12-31 | 34.86% |
| 2020-12-31 | 47.06% |
This slight downward trend highlights how Genmab A/S manages its overall profitability and cost control over time.
Comparing Genmab A/S's Net Margin to Peers
To better understand Genmab A/S's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Genmab A/S (GMAB.CO) | 5.55% |
| Nanobiotix SA (NANO.PA) | 586.89% |
| Vaccibody AS (VACC.OL) | 69.66% |
| Saniona AB (SANION.ST) | 56.39% |
| argenx SE (ARGX.BR) | 38.03% |
| Basilea Pharmaceutica AG Allschwil (BSLN.SW) | 37.21% |
Compared to its competitors, Genmab A/S's Net Margin is about average compared to peers, reflecting typical industry profitability.